FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biotechnology and Bioengineering

• Publication date

  2017-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/bit.26188PMID 27666939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carboxypeptidase D is the only enzyme responsible for antibody C‐terminal lysine cleavage in Chinese hamster ovary (CHO) cells

  2016cited by this paper
• It's time to regulate: Coping with product‐induced nongenetic clonal instability in CHO cell lines via regulated protein expression

  2014cited by this paper
• Chinese hamster ovary K1 host cell enables stable cell line development for antibody molecules which are difficult to express in DUXB11‐derived dihydrofolate reductase deficient host cell

  2013cited by this paper
• RNA-programmed genome editing in human cells

  2013cited by this paper
• RNA-Guided Human Genome Engineering via Cas9

  2013cited by this paper
• Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity

  2013cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• Introduction to current and future protein therapeutics: a protein engineering perspective.

  2011cited by this paper
• Highly efficient deletion of FUT8 in CHO cell lines using zinc‐finger nucleases yields cells that produce completely nonfucosylated antibodies

  2010influential reference
• Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.

  2010cited by this paper
• Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

  2008cited by this paper
• Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.

  2007influential reference
• Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC

  2007cited by this paper
• Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity

  2004cited by this paper
• Production of recombinant protein therapeutics in cultivated mammalian cells

  2004cited by this paper
• Fucose: biosynthesis and biological function in mammals.

  2003cited by this paper
• Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity*

  2002cited by this paper
• Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus

  2002cited by this paper
• IgG Fc receptors.

  2001influential reference
• Glycosylation and the immune system.

  2001influential reference
• Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

  2001cited by this paper
• Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics.

  2000cited by this paper
• Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

  1999cited by this paper
• IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation

  1998influential reference
• Molecular Cloning and Expression of GDP-d-mannose-4,6-dehydratase, a Key Enzyme for Fucose Metabolism Defective in Lec13 Cells*

  1998cited by this paper

• Regulatory mechanisms of core fucosylation and its progress in cancer therapy: from inhibitor development to antibody engineering.

  2025cites this paper
• Kinetic Dissection of the Reaction of Human GDP-l-Fucose Synthase

  2025cites this paper
• A gram-scale synthesis of β-L-carbafucose for engineering antibody glycans

  2025cites this paper
• N-Glycosylation modulators for targeted manipulation of glycosylation for monoclonal antibodies

  2025cites this paper
• Application of fucosylation inhibitors for production of afucosylated antibody

  2024cites this paper
• Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells

  2024cites this paper
• Interplay between de novo and salvage pathways of GDP-fucose synthesis

  2024cites this paper
• A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies

  2024cites this paper
• Stable overexpression of native and artificial miRNAs for the production of differentially fucosylated antibodies in CHO cells

  2024cites this paper
• Improving recombinant protein production in CHO cells using the CRISPR-Cas system.

  2023cites this paper
• Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

  2023cites this paper
• Development, methodological evaluation and application of a cell-based TRF assay for analysis of ADCC activity.

  2023cites this paper
• Recent advances in the application of genetic and epigenetic modalities in the improvement of antibody-producing cell lines.

  2023cites this paper
• Modulating antibody effector functions by Fc glycoengineering.

  2023cites this paper
• Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing

  2023cites this paper
• Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG

  2023cites this paper
• CRISPR‐interceded CHO cell line development approaches

  2023cites this paper
• An arrayed CRISPR screen reveals Myc depletion to increase productivity of difficult-to-express complex antibodies in CHO cells

  2022cites this paper
• Establishment of serum-free adapted Chinese hamster ovary cells with double knockout of GDP-mannose-4,6-dehydratase and GDP-fucose transporter

  2022cites this paper
• L‐fucose, a sugary regulator of antitumor immunity and immunotherapies

  2022cites this paper
• Sialylation as an Important Regulator of Antibody Function

  2022cites this paper
• Engineering nucleotide sugar synthesis pathways for independent and simultaneous modulation of N-glycan galactosylation and fucosylation in CHO cells.

  2022cites this paper
• Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S™ for enhancing FcγRIIIa binding and NK cell activation.

  2022cites this paper
• Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses

  2022cites this paper
• Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors

  2021cites this paper
• Antibody–receptor interactions mediate antibody-dependent cellular cytotoxicity

  2021cites this paper
• Genetic glycoengineering in mammalian cells

  2021cites this paper
• On the Use of Surface Plasmon Resonance Biosensing to Understand IgG-FcγR Interactions

  2021cites this paper
• Generation of FX −/− and Gmds −/− CHOZN host cell lines for the production of afucosylated therapeutic antibodies

  2020cites this paper
• Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.

  2020cites this paper
• Customized protein glycosylation to improve biopharmaceutical function and targeting.

  2019cites this paper
• Application of Genetic Engineering in Biotherapeutics Development

  2019cites this paper
• Glycoengineering of Antibodies for Modulating Functions.

  2019cites this paper
• Interaction of cell culture process parameters for modulating mAb afucosylation

  2019influential citation
• CRISPR/Cas9-Multiplexed Editing of Chinese Hamster Ovary B4Gal-T1, 2, 3, and 4 Tailors N-Glycan Profiles of Therapeutics and Secreted Host Cell Proteins.

  2018cites this paper
• The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

  2018cites this paper
• Improving titer while maintaining quality of final formulated drug substance via optimization of CHO cell culture conditions in low-iron chemically defined media

  2018cites this paper
• Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles

  2018cites this paper
• Antibody glycoengineering strategies in mammalian cells

  2018influential citation
• Glycoengineering of Mammalian Expression Systems on a Cellular Level.

  2018cites this paper
• Inhibition of fucosylation by 2-fluorofucose suppresses cell proliferation and migration as well as tumor formation

  2018cites this paper
• Metabolic engineering of CHO cells to prepare glycoproteins.

  2018cites this paper
• Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.

  2018cites this paper
• Cell Culture Processes for Biopharmaceutical Manufacturing

  2017cites this paper
• Afucosylated biosimilars need afucosylation specific assays

  2017cites this paper
• Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation

  2017cites this paper
• Procédés de fabrication de formes fucosylées et afucosylées d'une protéine

  2016cites this paper